Beneficial effect of an oral analog of prostacyclin on pulmonary hypertension secondary to congenital heart disease

Cardiology in the Young

Volumn 8, Issue 2, 1998, Pages 205-210

  Ichida, Fukiko ^a   Uese, Kei Ichiro ^a   Tsubata, Shin Ichi ^a   Hashimoto, Ikuo ^a   Hamamichi, Yuji ^a   Fukahara, Kazuaki ^a   Murakami, Arata ^a   Miyawaki, Toshio ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Congenital heart disease; Nitric oxide; Oral prostacyclin analog; Pulmonary hypertension

Indexed keywords

EID: 12344317378     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1047951100006090     Document Type: Article

References (15)

1. Bush A, Busst CM, Hawoth SG, Hislop AA, Knight WB, Corrin B, Shinebourne EA. Correlation of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J 1988; 59: 480-485.
2. Bush A, Busst C, Booth K, Knight WB, Shinebourne EA. Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease? Circulation 1986; 74: 135-144.
3. Schranz D, Zepp F, Iversen S, Wippermann C, Huth R, Zimmer B, Jungst BK, Oelert H. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992; 20: 1243-1249.
4. Roberts JD, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447-453.
5. Goldman AP, Delius RE, Deanfield JE, Macrae DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995; 60: 300-306.
6. Jones OD, Shore DF, Rigby ML, Leijala M, Scallan J, Shinebourne EA, Lincoln JC. The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children. Circulation 1981; 64(Suppl 11): 134-139.
7. Toda N. Beraprost sodium. Cardiovascular Drug Reviews 1988; 6: 222-238.
8. Takeo S. Pharmacodynamics and clinical studies with beraprost sodium, a drug for peripheral vascular disease. Cardiovascular Drug Reviews 1992; 10: 392-403.
9. Saji T, Ozawa Y, Aoki Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analog, Beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244-247.
10. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23-30.
11. Katz RW, Pollack MM, Weibley RE. Pulmonary artery catheterization in pediatric intensive care. Adv Pediatr 1984; 30: 169-190.
12. Day RW, Lynch JM, Shaddy RE, Orsmond GS. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1996; 75: 196-198.
13. Graham DR, Keldermans MM, Klemm LW, Semenza NJ, Shafer ML. Infectious complications among patients receiving home intravenous therapy, with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991; 91: 95S-100S.
14. Santak B, Schreiber M, Kuen P, Lang D, Radermacher P. Prostacyclin aerosol in an infant with pulmonary hypertension Eur J Pediatr 1995; 154: 233-235.
15. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440-446.